報價延遲最少15分鐘:2024/12/23 22:29 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.325 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-22.01/-2.86
|
|
企業價值
4.04M
|
| 資產負債 |
|
每股賬面淨值
0.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:29 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |